FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 279 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Datopotamab Deruxtecan High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer MOST POPULAR Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who... June 4, 2024 How Receiving My Own Cancer Diagnosis Changed My Perspective on Caring... August 25, 2020 Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45... January 15, 2022 EMA Recommends Extension of Indications for Datopotamab Deruxtecan August 21, 2026 Load more HOT NEWS Scientists uncover how incurable skin cancer resists treatment at the end... Coronavírus e COVID-19: o que as pessoas com câncer precisam saber ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic...
